Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva CEO Schultz: Only ‘Worst Cartel In History’ Would Cause Lower Prices

As US District Court Leans Towards Removing Focus On Teva In Civil Case

Executive Summary

Facing civil and criminal charges over alleged price fixing in the US, Teva looks to have succeeded in removing itself from the spotlight in the civil proceedings, having previously been selected as a priority for trial. CEO Kåre Schultz weighed in on the latest development.

You may also be interested in...



End Of Schultz Era Looms For Teva

Teva is expecting to have a new CEO by the end of next year, after current leader Kåre Schultz indicated that he was unlikely to renew his contract. The president and chief executive has overseen an eventful and transformative period for the Israeli firm.

Teva State Settlement On Price-Fixing Could Be First Of Many

Teva has struck a $950,000 deal to settle US price-fixing litigation with the state of Mississippi, in what the firm anticipates could be the first of multiple settlements with individual US states.

Unsealed US Price-Fixing Complaint Reveals ‘Diary Of Collusion’

Fresh details have been revealed in the ongoing saga of US generic price-fixing litigation, with a newly-published unredacted complaint disclosing excerpts from a notebook alleged to contain details of anti-competitive conduct.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel